Lyssikatos Joseph P's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Jan 22, 2026
- Accession no.
- 0001967150-26-000002
- Filed
- Jan 22, 2026
- Trade date
- Jan 20, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $535.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lyssikatos Joseph PCIK 0001967150 | Officer (CHIEF SCIENTIFIC OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 20, 2026 | Common Stock | SSaleDisposed | −5,491 | $26.37 | −$144,797.67 | 759,697 | Indirect | |
| Jan 20, 2026 | Common Stock | SSaleDisposed | −14,509 | $26.90 | −$390,292.1 | 745,188 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.